港股異動 | 生物醫藥板塊走強 君實生物(1877.HK)漲幅擴大至逾17%
格隆匯10月8日丨港股生物醫藥板塊走強,君實生物日內漲幅擴大至逾17%,復宏漢霖漲逾8%,再鼎醫藥漲近6%,嘉和生物漲近3%。

君實生物昨日公告,對BLAZE-1研究所進行的一項新期中分析數據顯示,LY-CoV555及JS016的聯合療法在降低病毒載量、減輕症狀及降低和冠狀病毒相關的住院及急診治療方面均顯示出良好療效。
10月4日,復宏漢霖宣佈,其正在開發的一款新冠病毒中和抗體HLX70針對新冠肺炎、新冠病毒引起的急性唿吸窘迫綜合徵(ARDS)或多重器官衰竭等適應症的新藥臨牀試驗申請(IND)獲得美國FDA的批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.